Comparison of clinical primary tumor site (PTS) response to induction chemotherapy (IC) with APF (<i>nab-</i>paclitaxel, cisplatin, and 5-FU) or APF plus cetuximab (APF+Cetux) in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
Jessica Ley(Washington University in St. Louis), Douglas R. Adkins(Washington University in St. Louis), Ravindra Uppaluri(Dana-Farber Cancer Institute), T. Rachocki, Jaisy Varges(Washington University in St. Louis), Brian Nussenbaum(Washington University in St. Louis), Jason T. Rich(Washington University in St. Louis), Randal C. Paniello, Wade L. Thorstad(Washington University in St. Louis), Tanya M. Wildes(University of Nebraska Medical Center), Hiram A. Gay(Washington University in St. Louis), Jason Diaz(Washington University in St. Louis), Loren S. Michel(Memorial Sloan Kettering Cancer Center)
Cited by 2
Related Papers
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial
|The Lancet Oncology|2013|748
NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018
|Journal of the National Comprehensive Cancer Network|2018|632
NCCN Guidelines® Insights: Head and Neck Cancers, Version 1.2022
|Journal of the National Comprehensive Cancer Network|2022|532